Holocene Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Holocene Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-598,800	Closed	-$142M	–	700
2022 Q4	$142M	Buy	598,800 +299,400	+100%	+$63.9M	0.87%	29
2022 Q3	$59.9M	Hold	299,400	–	–	0.38%	90
2022 Q2	$43.7M	Buy	+299,400	New	+$42.5M	0.26%	119
2022 Q1	–	Sell	-192,500	Closed	-$32.6M	–	861
2021 Q4	$32.6M	Sell	192,500 -381,500	-66%	-$70.9M	0.17%	155
2021 Q3	$108M	Buy	574,000 +329,000	+134%	+$61.7M	0.59%	46
2021 Q2	$41.5M	Buy	+245,000	New	+$35.9M	0.23%	135

Other funds holding ALNY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Holocene Advisors's ALNY Position: Q4 2025 in Review

Holocene Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2025, closing a stake of 13,086 shares — an estimated $5.97M sold.

Holocene Advisors first reported a position in ALNY in Q3 2019 and held it in 10 quarters. The position peaked at $195M in Q2 2025. 848 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

Holocene Advisors reported no remaining Alnylam Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Holocene Advisors sold 13,086 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $5.97M.
Holocene Advisors first reported a position in Alnylam Pharmaceuticals in Q3 2019 and held it in 10 quarters.
Holocene Advisors's Alnylam Pharmaceuticals position peaked at $195M in Q2 2025.
848 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on Holocene Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.